However, a minority of people with Alzheimer disease may benefit from the cholinesterase inhibitors, and further research is needed to identify these subgroups of people, considering, in particular, long-term and worthwhile improvements such as delay in institutionalization. Here, BCHE is linked to early-onset autosomal dominant Alzheimer disease.